ID   HEK-293T-hACE2
AC   CVCL_A7UK
SY   293T-ACE2
DR   BEI_Resources; NR-52511
DR   Wikidata; Q107115255
RX   PubMed=33495308;
CC   Group: SARS-CoV-2 research cell line.
CC   Characteristics: Expresses ACE2 under the control of the EF1a promoter (BEI_Resources=NR-52511).
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P03070; SV40 large T antigen.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:13557; ACE2.
CC   Transformant: NCBI_TaxID; 28285; Adenovirus 5.
CC   Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) (Note=tsA).
CC   Derived from site: In situ; Fetal kidney; UBERON=UBERON_0002113.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0063 ! HEK293T
SX   Female
AG   Fetus
CA   Transformed cell line
DT   Created: 20-05-21; Last updated: 10-04-25; Version: 8
//
RX   PubMed=33495308; DOI=10.1126/science.abf9302; PMCID=PMC7963219;
RA   Starr T.N., Greaney A.J., Addetia A., Hannon W.W., Choudhary M.C.,
RA   Dingens A.S., Li J.Z., Bloom J.D.;
RT   "Prospective mapping of viral mutations that escape antibodies used to
RT   treat COVID-19.";
RL   Science 371:850-854(2021).
//